NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals announced this week that it has initiated a Phase I trial of its RNAi-based hepatitis B therapy TKM-HBV, a key milestone for the company as it prepares to merge with HBV drug firm OnCore BioPharma.

TKM-HBV comprises siRNAs targeting several sites on the HBV genome and is delivered using Tekmira's lipid nanoparticles (LNPs). In preclinical testing, the drug has been shown to trigger reductions in HBV surface antigen, a key indicator of active infection, as well as cccDNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.